PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'EPI-PHARE, epidemiology of health products (French National Agency for Medicines and Health Products Safety, and French National Health Insurance), Saint-Denis Cedex, France; University of Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Anti-infective Evasion and Pharmacoepidemiology, CESP (Center for Research in Epidemiology and Population Health), Montigny le Bretonneux, France. Electronic address: noemie.roland@ansm.sante.fr.\', \'EPI-PHARE, epidemiology of health products (French National Agency for Medicines and Health Products Safety, and French National Health Insurance), Saint-Denis Cedex, France.\', \'Adolescent and Young Adult Gynaecology Unit and Reference Center for Rare, Diseases of Genital Development, AP.HP University of Paris Saclay, BicĂȘtre Hospital, Le Kremlin BicĂȘtre, France.\', \'EPI-PHARE, epidemiology of health products (French National Agency for Medicines and Health Products Safety, and French National Health Insurance), Saint-Denis Cedex, France; University of Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Anti-infective Evasion and Pharmacoepidemiology, CESP (Center for Research in Epidemiology and Population Health), Montigny le Bretonneux, France.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0010-7824(21)00464-910.1016/j.contraception.2021.12.002
?:doi
?:hasPublicationType
?:journal
  • Contraception
is ?:pmid of
?:pmid
?:pmid
  • 34971603
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.921
?:rankingScore_hIndex
  • 90
?:title
  • Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all